Tariffs push pharma onshoring debate

Eli Lilly said on February 26, 2025 that it would spend at least $27 billion on four new United States manufacturing sites, pushing its domestic capital commitments since 2020 above $50 billion. The announcement landed as President Donald Trump was pressing companies to move production back to the United States and threatening new import tariffs. (prnewswire.com) Drug plants are not like sneaker factories, where you can swap suppliers and restart a line in a few weeks. A new pharmaceutical site has to be built, inspected, validated, and matched to an approved manufacturing process before it can ship medicine at full scale. (fda.gov) That is why tariff pressure changes boardroom math long before it changes pill output. A tariff can hit on a political timetable, but a medicine plant usually moves on a multi-year timetable measured in concrete, equipment, and regulatory filings. (bdo.com) Lilly’s first big reveal was the national plan, but the sites started getting names later. In September 2025, the company picked Goochland County near Richmond, Virginia for a $5 billion plant expected to create 650 jobs and 1,800 construction jobs. (vedp.org) A week later, Lilly chose Houston for a $6.5 billion facility focused on small-molecule medicines, including orforglipron, its once-daily obesity pill candidate at the time. Texas said the project would cover about 1 million square feet and create 615 permanent jobs plus 4,000 construction jobs. (gov.texas.gov) In December 2025, Lilly named Huntsville, Alabama as the third site with a price tag above $6 billion. The company said that plant would make the chemical building blocks called active pharmaceutical ingredients, which are the core substances that make a drug work. (prnewswire.com) The tariff backdrop got harder, not softer. On April 2, 2026, the White House announced Section 232 tariffs on patented pharmaceuticals and related ingredients after a national security investigation found that only 15 percent of patented active pharmaceutical ingredients by volume for the United States market were produced domestically. (whitehouse.gov) That 15 percent figure helps explain why companies are talking about “site diversification” instead of one giant flagship plant. If one country, one supplier, or one factory becomes a choke point, a second approved site can work like a backup kitchen using the same recipe. (whitehouse.gov) In drug manufacturing, that recipe is not just ingredients and temperature. It is also batch records, equipment settings, cleaning steps, test methods, and the digital trail that proves a tablet made in Virginia matches a tablet made in Indiana. (fda.gov) That is why the quiet winners in an onshoring wave are often software and data systems rather than bulldozers. A company that can transfer a process from one site to another without rewriting every instruction by hand can bring a second factory online faster and with fewer quality surprises. (pharmtech.com) The catch is that reshoring does not automatically fix shortages. The Food and Drug Administration says shortages still stem from manufacturing and quality problems, delays, and discontinuations, which means a new domestic plant helps only if it can run reliably and pass inspection. (open.fda.gov) So the real shift is not “foreign plants out, American plants in.” It is a more expensive model where companies pay for duplicate capacity, duplicate documentation, and duplicate regulatory readiness so a tariff, a contamination event, or a border shock does not shut off a blockbuster drug. (fiercepharma.com)